As it fights loom­ing com­pe­ti­tion on Sub­ox­one, In­di­v­ior gets FDA OK on new schiz­o­phre­nia drug

British drug­mak­er In­di­v­ior got the green light from US reg­u­la­tors to sell its schiz­o­phre­nia drug Perseris — a re­lief, no doubt, con­sid­er­ing the com­pa­ny’s on­go­ing ex­clu­siv­i­ty war over its sta­ple drug Sub­ox­one.

This new­ly ap­proved med­i­cine, which used to be called RBP-7000, is a long-act­ing in­jectable de­liv­ered un­der the skin once per month. The drug con­tains risperi­done, a go-to treat­ment for schiz­o­phre­nia that’s al­ready FDA ap­proved. But In­di­v­ior’s ver­sion us­es an ex­tend­ed re­lease de­liv­ery sys­tem to form a de­pot that pro­vides sus­tained lev­els of the drug over the course of the month. The hope, In­di­v­ior says, is to help boost pa­tients’ ad­her­ence to tak­ing the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.